Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

61. Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial

Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial 28986942 2017 12 05 1365-2702 2017 Oct 06 Journal of clinical nursing J Clin Nurs Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial. 10.1111/jocn.14101 This study evaluates the clinical effectiveness of a multicomponent aroma-massage (...) with an acupressure treatment protocol and compared it to cognitive training for the management of behavioural and psychological symptoms of dementia. Pharmacological interventions have been unsatisfactory in managing behavioural and psychological symptoms of dementia; thus, complementary and alternative medicine has been extensively researched to identify an adjunct safe and cost-effective intervention. This randomised clinical trial utilised a three-arm parallel group design. Cognitive training was used

EvidenceUpdates2018

62. Less dementia with oral anticoagulation in atrial fibrillation

Less dementia with oral anticoagulation in atrial fibrillation 29077849 2017 10 27 1522-9645 2017 Oct 24 European heart journal Eur. Heart J. Less dementia with oral anticoagulation in atrial fibrillation. 10.1093/eurheartj/ehx579 The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without (...) oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect. Retrospective registry study of all patients with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014. Propensity score matching, falsification endpoints, and analyses according to intention to treat as well as on-treatment principles were used. The study included 444 106 patients and over 1.5 million years at risk. Patients

EvidenceUpdates2018

64. Randomised controlled trial: Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations

Randomised controlled trial: Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations Article Text Care of the older person Randomised controlled trial Self-management programme

Evidence-Based Nursing (Requires free registration)2018

66. Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines

Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness (...) and Guidelines Published on: December 19, 2017 Project Number: RB1177-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of using environmental restraints for geriatric patients with dementia or psychosis in long-term care facilities? What are the evidence-based guidelines regarding the use of environmental restraints for patients with dementia or psychosis in long-term care facilities? Key Message No relevant

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

67. Managing diabetes in people with dementia: a realist review

Managing diabetes in people with dementia: a realist review Managing diabetes in people with dementia: a realist review Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title (...) }} {{metadata.Headline}} Our review has resulted in six context mechanism outcome configurations which provide an explanatory account of how interventions might work to improve the management of diabetes in people living with dementia. {{author}} {{($index , , , , , , , , & . Frances Bunn 1, * , Claire Goodman 1 , Peter Reece Jones 2 , Bridget Russell 1 , Daksha Trivedi 1 , Alan Sinclair 3 , Antony Bayer 4 , Greta Rait 5 , Jo Rycroft-Malone 2 , Chris Burton 2 1 Centre for Research in Primary and Community Care

NIHR HTA programme2017

68. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: 18 F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18 F-florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18 F-florbetaben

Cochrane2017

69. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: 18 F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18 F-flutemetamol. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18 F-flutemetamol

Cochrane2017

70. Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees

Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees 28985260 2017 10 06 2017 10 06 1468-2834 2017 Sep 01 Age and ageing Age Ageing Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees. 1-7 10.1093/ageing/afx149 screening for cognitive impairment in Emergency Department (ED) requires short (...) , reliable tools. to validate the 4AT and 6-Item Cognitive Impairment Test (6-CIT) for ED dementia and delirium screening. diagnostic accuracy study. attendees aged ≥70 years in a tertiary care hospital's ED. trained researchers assessed participants using the Standardised Mini Mental State Examination, Delirium Rating Scale-Revised 98 and Informant Questionnaire on Cognitive Decline in the Elderly, informing ultimate expert diagnosis using Diagnostic and Statistical Manual of Mental Disorders (DSM-V

EvidenceUpdates2017

71. Polycystic kidney disease is significantly associated with dementia risk

Polycystic kidney disease is significantly associated with dementia risk 28855402 2017 08 31 2017 10 05 2017 10 05 1526-632X 89 14 2017 Oct 03 Neurology Neurology Polycystic kidney disease is significantly associated with dementia risk. 1457-1463 10.1212/WNL.0000000000004434 Data on the risk of neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD), in patients with polycystic kidney disease (PKD) are lacking. A total of 4,229 patients who were aged ≥20 years (...) and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression. The incidence density rates of dementia were 4.31 and 2.50 per 1,000 person-years in the PKD and control cohorts, respectively. A 2.04-fold

EvidenceUpdates2017

72. Can Angiotensin-Converting Enzyme Inhibitors Slow the Progression of Cognitive Decline In Elderly Patients With Dementia?

Can Angiotensin-Converting Enzyme Inhibitors Slow the Progression of Cognitive Decline In Elderly Patients With Dementia? "Can Angiotensin-Converting Enzyme Inhibitors Slow the Progression of C" by Karielle Brugman < > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Dementia is a slow progressing neurodegenerative disease characterized by loss of executive functioning (...) , communication ability, and activities of daily living. With few treatment options currently approved for dementia, angiotensin-converting enzyme inhibitors (ACE-I) have been implicated as a new potential treatment to slow cognitive decline. ACE-I use in dementia, however, is controversial due to conflicting research and new discoveries into the pathophysiology of the brain and ACE. This systematic review aims to evaluate the current research on ACE-I use in cognitive decline. Methods: Exhaustive search

Pacific University EBM Capstone Project2017

74. In geriatric adults with newly diagnosed dementia, does psychoeducation for their caregivers decrease caregiver burden or result in clinical improvement in the patient's dementia?

In geriatric adults with newly diagnosed dementia, does psychoeducation for their caregivers decrease caregiver burden or result in clinical improvement in the patient's dementia? In geriatric adults with newly diagnosed dementia, does psychoeducation for their caregivers decrease caregiver burden or result in clinical improvement in the patient's dementia? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features (...) of this site may not work without it. Search MOspace This Collection Browse Statistics In geriatric adults with newly diagnosed dementia, does psychoeducation for their caregivers decrease caregiver burden or result in clinical improvement in the patient's dementia? View/ Open Date 2017-06 Format Metadata Abstract In geriatric adults with newly diagnosed dementia, does psychoeducation for their caregivers decrease caregiver burden or result in clinical improvement in the patient's dementia? Evidence

Evidence Based Practice 2017

75. Challenge Demcare: Management of challenging behaviour in dementia at home and in care homes

Challenge Demcare: Management of challenging behaviour in dementia at home and in care homes Challenge Demcare: Management of challenging behaviour in dementia at home and in care homes Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata (...) .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} This research programme on dementia-care found neither staff training with on-line decision support interventions in care homes, nor treatment from NHS teams in the community, reduced clinically significant challenging behaviour {{author}} {{($index , , , , , , , , , , , , , & . Esme Moniz-Cook 1, 2, * , Cathryn Hart 2 , Bob Woods 3 , Chris Whitaker 4 , Ian James 5 , Ian Russell 6 , Rhiannon Tudor Edwards 7 , Andrea Hilton 1

NIHR HTA programme2017

76. Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence

Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence Managing Faecal INcontinence in people with advanced dementia resident in Care Homes (FINCH) study: a realist synthesis of the evidence Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try

NIHR HTA programme2017

77. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study.

Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. Objective To forecast dementia prevalence with a dynamic modelling approach that integrates calendar trends in dementia incidence with those for mortality and cardiovascular disease. Design Modelling study. Setting General adult population of England and Wales. Participants The English Longitudinal Study of Ageing (ELSA) is a representative panel study with six waves (...) of data across 2002-13. Men and women aged 50 or more years, selected randomly, and their cohabiting partners were recruited to the first wave of ELSA (2002-03). 11392 adults participated (response rate 67%). To maintain representativeness, refreshment participants were recruited to the study at subsequent waves. The total analytical sample constituted 17 906 people. Constant objective criteria based on cognitive and functional impairment were used to ascertain dementia cases at each wave. Main

BMJ2017

78. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public (...) , Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L & Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment 2017; 21(26) Authors' objectives To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community

Health Technology Assessment (HTA) Database.2017

79. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study.

Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. Objective To test the hypotheses that physical activity in midlife is not associated with a reduced risk of dementia and that the preclinical phase of dementia is characterised by a decline in physical activity. Design Prospective cohort study with a mean follow-up of 27 years. Setting Civil service departments in London (Whitehall II study). Participants 10 308 participants aged 35-55 (...) years at study inception (1985-88). Exposures included time spent in mild, moderate to vigorous, and total physical activity assessed seven times between 1985 and 2013 and categorised as "recommended" if duration of moderate to vigorous physical activity was 2.5 hours/week or more. Main outcome measures A battery of cognitive tests was administered up to four times from 1997 to 2013, and incident dementia cases (n=329) were identified through linkage to hospital, mental health services

BMJ2017

80. Assistive technology for memory support in dementia.

Assistive technology for memory support in dementia. BACKGROUND: The sustained interest in electronic assistive technology in dementia care has been fuelled by the urgent need to develop useful approaches to help support people with dementia at home. Also the low costs and wide availability of electronic devices make it more feasible to use electronic devices for the benefit of disabled persons. Information Communication Technology (ICT) devices designed to support people with dementia (...) are usually referred to as Assistive Technology (AT) or Electronic Assistive Technology (EAT). By using AT in this review we refer to electronic assistive devices. A range of AT devices has been developed to support people with dementia and their carers to manage their daily activities and to enhance safety, for example electronic pill boxes, picture phones, or mobile tracking devices. Many are commercially available. However, the usefulness and user-friendliness of these devices are often poorly

Cochrane2017